Show Notes
For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. These advances have transformed the outlook for people affected by HIV worldwide. In parallel, Gilead’s focus on catalytic collaborations at the global, national and local levels have helped to address the unmet needs of a wide range of individuals and communities. Jared Baeten is a physician, epidemiologist and head of R&D at Gilead Sciences who has spent decades working in partnership with collaborators around the world to help overcome the HIV epidemic. In this episode he discusses:
The current landscape of HIV research
Optionality and choice in HIV treatment and care
Beyond the lab: education, access and barriers to care
Achieving the collective vision of ending the HIV epidemic
This podcast was created by our partner Gilead Sciences and produced by New Scientist CoLab. Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit megaphone.fm/adchoices
More from New Scientist Colab Podcasts
💬 The longevity space isn’t just for humans. Science is uncovering new ways to keep our pets healthier for longer too. New research is finally uncovering why our dogs and cats slow down with age - and how we can slow that process.
💬 Over the last decade, advances in subsurface imaging have meant we’re able to see deep within our planet with unfathomable detail - pinpointing vast geological structures beneath our oceans with unprecedented accuracy.
The production of medicines is a high-stakes industry where efficiency and environmental impact often collide. Given that the pharmaceutical industry is one of society’s biggest polluters, solving this challenge requires massive, cross-continent collaboration to spark real change.